Biologics

All articles by Biologics

Pfizer’s Hospira deal shores up established product division
Pfizer’s Hospira deal shores up established product division
Deborah Weinstein
February 5, 2015
6:00 pm

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Five things for pharma marketers to know: Wednesday, February 4
Five things for pharma marketers to know: Wednesday, February 4
Kevin McCaffrey
February 4, 2015
3:30 pm

One in three adults would rather not take a pill and have a shorter life span; Pfizer’s next-gen breast-cancer drug nabs an early approval; Amgen’s Humira biosimilar demonstrates clinical equivalence.

Novartis psoriasis drug approval could upend market
Novartis psoriasis drug approval could upend market
Kevin McCaffrey
January 21, 2015
8:00 pm

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen’s Enbrel and J&J’s Stelara.

Five things for pharma marketers to know: Monday, January 5
Five things for pharma marketers to know: Monday, January 5
David Vaczek
January 5, 2015
5:02 pm

Severe flu season to test Roche’s Tamiflu; Novartis gains nod for psoriasis drug; Amgen and Kite collaborate on immunotherapy.

MM&M’s top reads of 2014
MM&M’s top reads of 2014
December 31, 2014
5:21 pm

A look at the content that grabbed most reader interest over the past year.

FDA plans review of Sandoz’s Neupogen biosimilar
FDA plans review of Sandoz’s Neupogen biosimilar
December 10, 2014
8:16 pm

As courts sort out lawsuits over two Sandoz biosimilars, the Novartis unit reports a study showing its BLA candidate has similar efficacy to Neupogen.

Amgen releases Humira biosimilar data
Amgen releases Humira biosimilar data
October 8, 2014
5:20 pm

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Lilly takes on Amgen’s Enbrel
Lilly takes on Amgen’s Enbrel
Deborah Weinstein
August 21, 2014
5:27 pm

Phase-III tests indicate Lilly’s experimental treatment bests Amgen’s for moderate-to-severe plaque psoriasis.

Investors want end to biosim trash talk
Investors want end to biosim trash talk
August 11, 2014
5:51 pm

A group of investors has drawn up a list of business principles which includes not disparaging biosimilars as being inferior to branded biologics.

Senators ask FDA for biosimliar naming rules
Senators ask FDA for biosimliar naming rules
August 5, 2014
5:17 pm

Soonish would be good, since a Novartis subsidiary filed a biosimilar with the FDA last month.

  • From Our Partners